In the April 2023 issue of Transfusion Medicine and Hemotherapy, Strengers reviewed future challenges for plasma-derived medicinal products. The review nicely describes the current situation of the global plasma market and its impact on the supply of plasma-derived medicinal product for treatment of patients suffering from immunodeficiency, deficiencies of coagulation factor, inhibitors, etc. . As most source plasma is collected in the USA, intensive national donor campaigns and recruitment programs are necessary to increase plasma collections outside the USA, thereby reducing dependency on international supply chains .
Personalized plasmapheresis is an approach to optimize the donation volume without compromising donor safety. Studies from the USA and Germany showed that intensified plasmapheresis is feasible and safe provided that the donor is closely monitored [3‒5]. National guidelines allow for a default donation volume based on donor’s body weight. In Table 1 of Strengers’ review, we noticed that the body weight and the donation volume were not correctly cited for German and US donors.
Choosing the correct donation volume based on donors’ body weight is of utmost importance to avoid or reduce adverse donation-associated events.
Conflict of Interest Statement
The authors are employees at Octapharma Plasma GmbH.
No funding was received.
R.M. drafted the manuscript. All authors critically reviewed, revised, and approved the final version of the manuscript.